Kymera Therapeutics (KYMR) Stock News

$KYMR · NASDAQ · 2 stories in 30 days

BORSA has published 2 stories on Kymera Therapeutics (KYMR) in the past 30 days. BORSA’s news read on KYMR is bullish at 64/100, −1 over 24 hours, based on 2 company events over the past 30 days. KYMR last closed at $106.68 on Oct 13, up 0.66% over five sessions and down 6.94% over the past month. Kymera Therapeutics’ next earnings report is scheduled for Tuesday, Nov 3.

The wire on $KYMR

newest first · updated Oct 9, 8:49 AM ET · direct subject stories only

Analyst actionOct 9 · 8:49 AM ET

Raymond James initiates Kymera Therapeutics coverage with Outperform rating and $140 price target

Raymond James initiated coverage on Kymera Therapeutics.

bullish 70 · impact 40

Kymera Therapeutics receives a positive analyst rating: a large microscope focuses on a molecular structure above an upward-pointing arrow.

← Stocks · in the newsroom

Kymera Therapeutics (KYMR) Stock News

$KYMR · NASDAQ · 2 stories in 30 days

The wire on $KYMR

newest first · updated Oct 9, 8:49 AM ET · direct subject stories only

Analyst actionOct 9 · 8:49 AM ET

Raymond James initiates Kymera Therapeutics coverage with Outperform rating and $140 price target

Raymond James initiated coverage on Kymera Therapeutics.

bullish 70 · impact 40

Frozen company-score outcomes

One recorded score per stock and trading day. Evidence and method are fixed before the measured returns. Later news cannot rewrite those predictions.

Horizon	Coverage	Vs SPY match	Vs sector match	Stock median	Vs SPY median	Vs sector median
1 hour	0 measured · 0 days · 0 pending · 9 unavailable	Collecting (0/30)	Collecting (0/30)	—	—	—
Next session close	0 measured · 0 days · 0 pending · 9 unavailable	Collecting (0/30)	Collecting (0/30)	—	—	—
Fifth subsequent session close	0 measured · 0 days · 0 pending · 9 unavailable	Collecting (0/30)	Collecting (0/30)	—	—	—

Method ticker-news-v4. Direction match appears only after 30 scored trading days per horizon. Neutral scores and benchmark moves within ±0.05% are unscored. Five-session outcomes overlap; observations are not independent trials. These are price returns, not dividend-reinvested returns. This is observation, not established predictive accuracy.

Kymera Therapeutics (KYMR) Stock News

The wire on $KYMR

Kymera Therapeutics (KYMR) Stock News

The wire on $KYMR

The wire on this name is open. What the tape did about it is one free account away.

Kymera Therapeutics (KYMR) stock: common questions

What is the latest Kymera Therapeutics stock news?

Is the news on KYMR bullish or bearish?

When does Kymera Therapeutics report earnings?

How has KYMR stock moved recently?

Frozen company-score outcomes